BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26271008)

  • 21. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
    Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
    J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
    Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
    Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
    Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
    Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
    Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
    He C; Li L; Guan X; Xiong L; Miao X
    Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ubiquitination and degradation of mutant p53.
    Lukashchuk N; Vousden KH
    Mol Cell Biol; 2007 Dec; 27(23):8284-95. PubMed ID: 17908790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
    Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
    Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
    Zhang Y; Hu Y; Fang JY; Xu J
    Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMGA2 promotes intestinal tumorigenesis by facilitating MDM2-mediated ubiquitination and degradation of p53.
    Wang Y; Hu L; Wang J; Li X; Sahengbieke S; Wu J; Lai M
    J Pathol; 2018 Dec; 246(4):508-518. PubMed ID: 30175854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
    D'Arcy P; Maruwge W; Ryan BA; Brodin B
    Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
    Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
    Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
    Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
    Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
    Olotu FA; Soliman MES
    J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.